
News|Articles|July 2, 2018
- Pharmaceutical Technology\'s In the Lab eNewsletter-07-03-2018
- Volume 13
- Issue 7
Sciex’s New Mass Spec Technologies Enhance Lab Analytics
Author(s)Pharmaceutical Technology Editors
Sciex’s latest additions to its biopharma portfolio helps to optimize workflow for better analytics in the lab.
Sciex’s latest additions to its biopharma portfolio help to optimize workflow for better analytics in the lab.
According to the company, these products have been optimized for maximal sensitivity, accuracy, and efficiency for scientists using challenging workflows in critical fields without sacrificing robustness or ease of use.
Recent additions to the Sciex biopharma portfolio include:
- OptiFlow Quant Solution, which delivers highly sensitive micro-flow quantitation for peptides. This solution includes the OptiFlow Turbo V Source with M5 MicroLC to deliver micro-flow sensitivity at analytical flow usability, with flexible and user-friendly sample handling.
- Multiple Attribute Methodology (MAM) Workflow for simplified, in-depth liquid chromatography-mass spectrometry characterization and development of biologics. The MAM Workflow provides complete analysis of the product quality profile while minimizing the burden of product-quality attribute monitoring and product purity testing and uses the company’s BioPharmaView 3.0 software.
- the SCIEX OS 1.4 software brings the full package for quantitative and qualitative analysis to the majority of SCIEX instruments. The new operating system also offers complete 21 CFR Part 11 compliance for labs in regulated fields.
- the MPX 2.0 software, which was recently developed for multiplexing liquid chromatography separations within a single mass spectrometry system, saves valuable laboratory time while improving flexibility, according to the company.
The company showcased these innovations at ASMS 2018 on June 3–7, 2018 in San Diego, CA.
Source:
Articles in this issue
about 8 years ago
Dissolution Testing: Keeping It Simpleabout 8 years ago
Improvements Needed for Adventitious Agent Testingabout 8 years ago
Alcami Expands Laboratory Services Programabout 8 years ago
Shimadzu’s New Q-TOF System Enhances Mass Spectrometryover 8 years ago
Waters’ New UPLC Platform Meets Evolving Chromatography Needsover 8 years ago
Juniper Pharma Services Expands Laboratory Facilitiesover 8 years ago
Micromeritics Acquires Freeman TechnologyRelated to this article

Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.

This article discusses risk-based lifecycle governance, system implementation considerations, and the progression of batch record control from paper-based to fully electronic systems.

Ronald Piervincenzi, USP, explains why manufacturers should act now and how benchmarking could reward reliable generic drug suppliers.

The FDA approves Lilly's once-weekly insulin efsitora for type 2 diabetes, raising Fc-fusion manufacturing, high-concentration pen, and capacity questions.

Florin Muraru, Gourav Pandey, and Richard Jaenisch explain where human sign-off belongs as multi-agent AI and document-parsing models reach GxP.

In this episode of Ask the Expert, Siegfried Schmitt, PhD, vice president, Technical at Parexel, and Susan J. Schniepp, distinguished fellow at Nelson Labs, discuss how companies should approach post-approval changes to their CMC regulatory filings.

The EC has approved AstraZeneca's Trixeo Aerosphere as the first single-inhaler triple-combination therapy for asthma in the EU, based on phase e data showing improved lung function and fewer severe exacerbations in patients uncontrolled on standard ICS/LABA treatment.
Trending on Pharmaceutical Technology
1
Pharma Fundamentals: Digital Pathology in Drug Development, Part 1
2
PharmTech’s Weekly Roundup—September 25, 2026
3
EU Clears AstraZeneca's Trixeo for Asthma, Opening New Manufacturing Demand for Single-Inhaler Triple Therapy
4
Weekly Basal Insulin Efsitora: A New Biologics CMC Benchmark
5

